Navigation Links
SuperGen Reports 2008 Third Quarter Financial Results
Date:11/4/2008

ion, or $0.11 per share, compared with net income of $7.9 million, or $0.14 per share, for the same prior year period. The net loss for the nine months ended September 30, 2008 includes a non-operating charge of $3.1 million that reflects an other than temporary decline in value of the Company's equity investments.

As of September 30, 2008, the Company had approximately $88.7 million in current and non-current unrestricted cash, cash equivalents and marketable securities.

2008 Financial Guidance

The Company has revised its royalty revenue upward from previous guidance for 2008 to range from $33 million to $36 million. The Company recognizes royalty revenue on a cash basis when it is received. The Company has reduced its anticipated milestone receipts relating to the sale of products to Mayne Pharma to $1.8 million for 2008. Research and development expenses for 2008 have been revised downward and are expected to total approximately $33 million to $35 million. The growth over 2007 continues to be influenced by increasing costs related to clinical trial programs such as MP-470, ongoing pre-clinical product development efforts and investments in the discovery, pre-clinical, manufacturing, regulatory and clinical development operations of the Company. The Company expects to record a charge during 2008 of approximately $5.2 million for acquired in-process research & development resulting from a milestone payment to the former Montigen stockholders. This payment is contingent on the filing of an Investigational New Drug (IND) application (and upon the IND going into effect) with the Food and Drug Administration (FDA) of a second drug emanating from the acquired technology. Selling, general and administrative expenses are expected to be lower from previous guidance and are forecasted to be approximately $12 million for 2008. Included in 2008 total operating expenses are non-cash stock-based compensation expenses of approximately $3 million. Based on th
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. SuperGen Reports 2008 Second Quarter Financial Results
10. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
11. SuperGen to Present Data at EORTC-NCI-AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013   NineSigma , Inc., of ... its launch, NineSights.com is now the innovation ... the worldwide community of innovators. From technology ... experts, NineSights stands out for its large community of ... technical disciplines, all vetted by NineSigma. The community is ...
(Date:6/19/2013)... , June 19, 2013 Biotechnology industry pioneer ... up with financial software provider BlackLine Systems  and ... SAP ) for a webinar next week entitled ... Solutions from BlackLine and SAP to Help Keep Its Account ... http://photos.prnewswire.com/prnh/20061117/LAF027LOGO ) The webinar, geared at ...
(Date:6/19/2013)... Canada (PRWEB) June 19, 2013 ... trial business can potentially be worth up to ... this opportunity, the Indian government is taking serious ... trials the process. , This presentation will examine:, ... trial regulations ,     Immediate and long term ...
(Date:6/19/2013)... Blue Earth, MN (PRWEB) June 19, 2013 ... drugs of abuse tests, today announced that it has ... Canada to market and sell its DrugCheck® NxStep ... licensure allows use of the rapid screening device in ... NxStep Onsite Drug Screen Cup received Health Canada Class ...
Breaking Biology Technology:NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... first time, researchers have developed a 3D picture of ... of the human cellular machinery, enhancing our understanding of ... opening up new possibilities for stepping in to prevent ... many tactical manoeuvres employed by the virus. The ...
... (Nasdaq: BIOD ) today announced that Dr. ... present a corporate update at the 29th Annual JPMorgan ... a.m. Pacific Time (12:30 p.m. Eastern Time). The update ... formulations of its lead product, Linjeta™, including milestones and ...
... Biosciences, Inc. (Nasdaq: RDEA ) today announced ... of RDEA594 in combination with the current standard of ... accounts for greater than 90% of the unit sales ... only 30-40% of gout patients respond adequately to allopurinol ...
Cached Biology Technology:Researchers visualize herpes virus' tactical maneuver 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 4Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 5Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 6Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 7
(Date:6/18/2013)... Scientists at the University of Calgary,s Faculty of Medicine ... the body from harmful bacteria. Platelets, a component of ... search for specific bacteria, and upon detection, seal it ... which were published in Nature Immunology this ... of immunity. , "The science community has known that ...
(Date:6/18/2013)... At Brandeis University, sophisticated computational models and advances ... the complex interplay between genomic data, virus structure ... critical for replication. , "We ... will help researchers alter virus assembly, leaving viruses ... first author of the scientific paper describing the ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
Breaking Biology News(10 mins):Immunity mechanism discovered 2Computer modeling technique goes viral at Brandeis 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... 4, 2010 -- Supercomputer simulations at the Department of Energy,s ... acids could have contributed to the origins of life. ... directs ORNL,s Center for Molecular Biophysics and holds a Governor,s ... probe an organic chemical reaction that may have been important ...
... USA (October 4, 2010) The Aeras Global TB ... grant from the United States Food and Drug Administration ... TB vaccine development. The FDA grant, which supports the ... United States, the United Kingdom and South Africa, will ...
... Major, PhD, assistant professor of cell and developmental biology, ... Health Director,s New Innovator Awards, one of the NIH,s ... fund his work to address a significant medical science ... contribute to specific cellular and disease processes such as ...
Cached Biology News:Powerful supercomputer peers into the origin of life 2Aeras-led research consortium receives FDA support 2UNC scientist receives NIH director's New Innovator Award 2
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
Biology Products: